Abstract
Human papillomaviruses (HPV) are the most important causes of cervical cancer but also other carcinomas and non-malignant lesions especially of women's and men's genital area. But not only.
Prevention of HPV infection is the primary prevention of all HPV-associated lesions. Ten years ago clinical history of HPV vaccination has started by quadrivalent vaccine.
In 2015 it was graduated by nonavalent vaccine. All HPV vaccines are characterized by high efcacy against including types of HPV and also high safety.
Observation studies illustrate the decrease of genital warts and cervical changes prevalence in vaccinated popula- tion. Two doses vaccination schema, partial health insurance cover for nonavalent vaccine and gender balance for boys could improve percentage of vaccinated teenagers in Czech Republic.